Réunion commune de la SFN et de la SFNV, 8–10 octobre 2008Post-stroke depressionDépression postaccident vasculaire cérébral
Introduction
Over the last 50 years, there has been a steady decline in stroke incidence and mortality. The improved acute management of stroke patients is the most important factor contributing to this decline. Nevertheless, about two-thirds of stroke patients remain with some degree of permanent disability that requires rehabilitation care (Chemerinski and Robinson, 2000).
Stroke survivors may present neuropsychiatric (NP) disorders resulting in a negative effect not only on social interactions and on the overall quality of life, but also on the recovery of their motor function. Depression, anxiety disorder, catastrophic reaction or psychosis are frequently observed after stroke (Chemerinski and Robinson, 2000). Because of their impact on quality of life, NP disorders should be promptly recognized and treated.
Post-stroke depression (PSD) could be defined as depression occurring in the context of a clinically apparent stroke and is the most frequent psychiatric complication of cerebrovascular lesions (Chemerinski and Robinson, 2000).
Section snippets
Epidemiology
The mean prevalence of PSD has been estimated to be around 30–35%, ranging from 20 to 60% (Paolucci et al., 2005). This high variability of the prevalence rate is essentially due to methodological problems: different diagnostic criteria applied, use of various depression rating scales, different timing of evaluation, different criteria for patients’ enrolment (Paolucci et al., 2005). Verdelho et al. (2004) in their prospective study have preferred to evaluate depressive symptoms as a
Diagnosis
The diagnosis of PSD is challenging in the acute and chronic aftermath. Therefore, it often remains unrecognized and undertreated.
Despite adopting a non etiological view, the DSM-IV criteria for PSD are: a diagnosis of “depression due to stroke with major depressive-like episode or depressive features”. One of the major problems with the DSM-IV criteria for PSD is related to the fact that the diagnosis also requires the presence of some somatic symptoms (weariness, energy loss, weight loss,
Premorbid risk factors
Risk factors related to PSD are constitutional (female gender), clinical (previous stroke, previous depressive or psychiatric episode, cognitive impairment or aphasia), functional (severity of disability); environmental (premorbid neurotic personality and social isolation), biological (family history of depression [both genetic and environmental – “double biological hit”]). Other risk factors such as education level, previous stroke, stroke severity, apathy, denial reaction at the acute stage,
Etiology
PSD pathophysiology is still debated. Either a biological hypothesis (ischemic insults affecting neural circuits involved in mood regulation) or a psychosocial hypothesis (social and psychosocial stressors associated with stroke are in fact a primary cause of depression) has been taken into consideration, but there is no definitive evidence to support or refute one of these hypothesis (Whyte and Mulsant, 2002).
With regard to biological mechanism, there are the following statements: on the one
Prognosis
The clinical relevance of depression following stroke is related to the increased risk of death, exalted caregiver burden, worsening of the cognitive impairment, and negative influence on functional recovery. PSD is an independent predictor of poor short-term and long-term (12–24 months) post-stroke functional outcome. Remission of PSD over the first few months after stroke is associated with greater recovery in activities of daily living functions (Chemerinski et al., 2001).
It seems that the
Treatment
Early effective treatment of depression may have a positive effect not only on depressive symptoms but also on the rehabilitation outcome of stroke patients.
Treated patients with PSD showed significantly better functional improvement than untreated ones (mainly fluoxetine and nortriptyline within one month after stroke).
In clinical practice, only a minority of the patients with PSD are diagnosed, and even fewer are treated, mainly because of the high frequency of contraindications, adverse
Conclusion
Depression is a frequent and serious complication after stroke for the possible negative repercussions on patients’ recovery.
The evidence available on the therapeutic indications and especially on the possibility of preventive interventions is still limited, although promising.
Large trials are needed to limit the impact of this complication. Implementing preventive and therapeutic strategies to reduce the risk of abnormal mood and thus improve rehabilitation outcomes would appear important in
References (15)
- et al.
The Neuropsychiatry of stroke
Psychosomatics
(2000) - et al.
Detection of depression in the stroke patient
Psychosomatics
(1992) - et al.
Post-stroke depression: epidemiology, pathophysiology, and biological treatment
Biol Psychiatry
(2002) - American Psychiatric Association. DSM-IV-TR. Diagnostic and Statistical manual of mental disorders. 4th ed. Text...
- et al.
Risk factor for post-stroke depression
Intern J Geriatr Psychiatry
(1997) - et al.
Improved recovery in activities of daily living associated with remission of post-stroke depression
Stroke
(2001) Depression in stroke patients 7 years following stroke
Acta Psychiatr Scand
(2001)
Cited by (73)
Forgetful, sad and old: Do vascular cognitive impairment and depression share a common pre-disease network and how is it impacted by ageing?
2022, Journal of Psychiatric ResearchCitation Excerpt :Interestingly, this overall pooled estimate was not significantly different when studies accounted for a prior history of depression (Hackett and Pickles, 2014). Post-stroke depression (PSD) is a clinical entity defined in the DSM-V as a mood disorder with depressive features due to CVA (Lenzi et al., 2008; Robinson and Jorge, 2016), and has been explained by focal damage to catecholaminergic and serotonergic neural circuits, particularly frontal-subcortical pathways directly affected by infarction (Bonavita et al., 2001; Göthe et al., 2012). Current evidence regarding associations between ischaemic territory and depression risk are inconsistent, likely due to heterogeneity in timing and assessment tolls used (Wei et al., 2015).
Ischemic stroke and depression
2022, Bulletin de l'Academie Nationale de MedecineEmerging Knowledge of the Neurobiology of COVID-19
2022, Psychiatric Clinics of North AmericaCitation Excerpt :As has been noted, patients with COVID-19 are predisposed to cerebrovascular pathology, including acute stroke.8 It is well known that the incidence of depression is high following stroke.41 In addition, multiple neuroimaging studies in patients with COVID-19 (typically severe cases) have consistently shown structural brain lesions, particularly in white matter tracts.42
An iPad application-based intervention for improving post-stroke depression symptoms in a convalescent rehabilitation ward: A pilot randomized controlled clinical trial protocol
2020, Internet InterventionsCitation Excerpt :PSD, a chronic disease with a significant negative impact on the prognosis of stroke patients, is a serious complication after stroke and affects approximately 30% of stroke patients (Tam and Bayley, 2018; Ayerbe et al., 2014; Hackett and Pickles, 2014; Hackett et al., 2005). PSD is also frequently unresponsive to convention treatment, and only 15%–50% of patients are reported to recover one year after PSD onset (Ayerbe et al., 2013; Berg et al., 2003; Kouwenhoven et al., 2011; Lenzi et al., 2008; Whyte and Mulsant, 2002). Clinical manifestations of PSD include depressed mood as the main symptom but also apathy, weight loss or gain, sleep disturbances, fatigue, feelings of worthlessness, and anhedonia (Feng et al., 2014).